Treatment also significantly reduced active caspase-1, IL-1β, and ASC specks (P = 0.0162, 0.0050, 0.0016, respectively) (Figure 5G), indicating that RNAP3 inhibition attenuated inflammasome activity in primary MDS specimens. The gene discussed is IL1B; the disease is myelodysplastic syndrome.